This phase II, multicenter, open-label study is studying Daratumumab in combination with weekly Carfilzomib, Pomalidomide, and Dexamethasone in people with relapsed and refractory Multiple Myeloma who have received at least one prior therapy and who have had previous treatment with both Lenalidomide and a Proteasome inhibitor.
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves two study drugs and two standard of care drugs. - The names of the study drugs involved in this study are: - Carfilzomib - Daratumumab - The names of the standard of care drugs involved in this study are: - Dexamethasone - Pomalidomide - A total of 43 participants will be enrolled to this trial - The U.S. Food and Drug Administration (FDA) has not approved Daratumumab, and Carfilzomib for use in treatment of Multiple Myeloma.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
The following is a listing of trial locations that are open and accepting patients.
There are no resources, links or videos to display for this clinical trial.